A sensitive method for the quantification of fluticasone propionate in human plasma by high-performance liquid chromatography atmospheric pressure chemical ionisation mass spectrometry

被引:23
作者
Li, YN
Tattam, BN
Brown, KF
Seale, JP
机构
[1] UNIV SYDNEY,DEPT PHARM,SYDNEY,NSW 2006,AUSTRALIA
[2] UNIV SYDNEY,DEPT PHARMACOL,SYDNEY,NSW 2006,AUSTRALIA
关键词
fluticasone propionate; reverse-phase liquid chromatography; atmospheric pressure chemical ionisation mass spectrometry;
D O I
10.1016/S0731-7085(97)00073-3
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
A highly sensitive and selective method has been developed for the quantification of fluticasone propionate (FP) in human plasma. The drug was isolated from human plasma using C-18 solid-phase extraction cartridges. The analysis was based on high-performance liquid chromatography/atmospheric pressure chemical ionisation mass spectrometry (HPLC/APCI/MS), using the 22R epimer of budesonide (BUD) acetate, synthesised using acetic anhydride, as internal standard. The mass spectrometer was operated in APCI mode with selected ions at tune masses of 473.2 and 501.2 m/z, corresponding to the MH+ of acetylated (22R)BUD and FP, respectively. The mobile phase used was a mixture of 50% ethanol in water with a flow rate of 0.45 ml min(-1). The system was optimised by tuning the capillary and tube lens with a concentrated solution of FP. The recovery of FP from human plasma was 86.3%. Linearity of response was obtained over the concentration range 0.2-4.0 ng ml(-1). The intra-assay and inter-assay variability were 6.3 and 2.9%, respectively. The lower limit of quantification was 0.2 ng ml(-1) when a solid-phase extraction preceded the HPLC/APCI/MS. (C) 1997 Elsevier Science B.V.
引用
收藏
页码:447 / 452
页数:6
相关论文
共 14 条
[1]  
ANDERSSON N, 1994, THORAX, V49, pP442
[2]  
[Anonymous], 1990, DETECTION ORIENTED D
[3]   A SENSITIVE RADIOIMMUNOASSAY, INCORPORATING SOLID-PHASE EXTRACTION, FOR FLUTICASONE 17-PROPIONATE IN PLASMA [J].
BAIN, BM ;
HARRISON, G ;
JENKINS, KD ;
PATEMAN, AJ ;
SHENOY, EVB .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1993, 11 (07) :557-561
[4]  
BARNES NC, 1993, EUR RESPIR J, V6, P877
[5]   FLUTICASONE PROPIONATE - AN UPDATE ON PRECLINICAL AND CLINICAL-EXPERIENCE [J].
FULLER, R ;
JOHNSON, M ;
BYE, A .
RESPIRATORY MEDICINE, 1995, 89 :3-18
[6]   AN ASSESSMENT OF THE SYSTEMIC ACTIVITY OF SINGLE DOSES OF INHALED FLUTICASONE PROPIONATE IN HEALTHY-VOLUNTEERS [J].
GRAHNEN, A ;
ECKERNAS, SA ;
BRUNDIN, RM ;
LINGANDERSSON, A .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 38 (06) :521-525
[7]   A COMPARISON OF THE SYSTEMIC BIOACTIVITY OF INHALED BUDESONIDE AND FLUTICASONE PROPIONATE IN NORMAL SUBJECTS [J].
GROVE, A ;
ALLAM, C ;
MCFARLANE, LC ;
MCPHATE, G ;
JACKSON, CM ;
LIPWORTH, BJ .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 38 (06) :527-532
[8]   THE HUMAN PHARMACOLOGY OF FLUTICASONE PROPIONATE [J].
HARDING, SM .
RESPIRATORY MEDICINE, 1990, 84 :25-29
[9]   Determination of epimers 22R and 22S of budesonide in human plasma by high-performance liquid chromatography atmospheric pressure chemical ionization mass spectrometry [J].
Li, YN ;
Tattam, B ;
Brown, KF ;
Seale, JP .
JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1996, 683 (02) :259-268
[10]   DETERMINATION OF (22R,S)BUDESONIDE IN HUMAN PLASMA BY AUTOMATED LIQUID-CHROMATOGRAPHY THERMOSPRAY MASS-SPECTROMETRY [J].
LINDBERG, C ;
BLOMQVIST, A ;
PAULSON, J .
BIOLOGICAL MASS SPECTROMETRY, 1992, 21 (11) :525-533